Celon Pharma's generic semaglutide drug matches Ozempic in early study, shares jump
Celon Pharma's generic semaglutide drug matches Ozempic in early study, shares jump Aug 20 (Reuters) - Celon Pharma's CLNP.WA experimental semaglutide product Reduzek, a generic alternative to Novo Nordisk's NOVOb.CO Wegovy and Ozempic, matched the blockbuster weight-loss drugs in an early-stage bioequivalence study, the Polish drugmaker said on Thursday.
The company's shares surged 14.7% following the publication of selected data from the study, and were on track for their best trading day since July 2024 if the gains hold.
The Canadian study on 91 healthy volunteers showed a 0.5 milligram dose of Reduzek had a comparable rate and extent of absorption to Ozempic and Wegovy.
The data will allow Celon Pharma to extend the demonstrated bioequivalence to other doses of the drug candidate, according to clinical guidelines.
It said the trial marks a significant step in its strategy to launch the semaglutide equivalent in global markets.
The company's portfolio includes antipsychotic medicine Ketrel, the anti-tumor drug Aromek and Alzheimer's disease treatment Donepex.
(Reporting by Marta Maciag in Gdansk, editing by Milla Nissi-Prussak)
((Marta.Maciag@thomsonreuters.com;))
Recent news on Celon Pharma SA
See all newsBrief: Celon Pharma Projects Recommended For About 29.9 Mln Zlotys Funding By Poland's Medical Research Agency
Brief: Celon Pharma Files Marketing Authorization Applications In EU For Semaglutide Drug Injection Solution
Brief: Celon Pharma Q2 Net Loss At 30.6 Million Zlotys
Brief: Celon Pharma Gets Positive Opinion Confirming Reduzek Compliance With Safety Requirements
Celon Pharma's generic semaglutide drug matches Ozempic in early study, shares jump